Back to User profile » Dr Kamal Kant Singh Abbi
Paper published by Dr Kamal Kant Singh Abbi:
Original Research
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
Nadiminti K, Singh Abbi KK, Mott SL, Dozeman L, Tricot A, Schultz A, Behrends S, Zhan F, Tricot G
OncoTargets and Therapy 2017, 10:217-226
Published Date: 6 January 2017